Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 10.3322/caac.21660 Samaratunga, 2012, Recently described and unusual variants of urothelial carcinoma of the urinary bladder, Pathology, 44, 407, 10.1097/PAT.0b013e3283560172 von der Maase, 2005, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J Clin Oncol, 23, 4602, 10.1200/JCO.2005.07.757 Park, 2020, Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options, Korean J Intern Med, 35, 834, 10.3904/kjim.2020.204 Bellmunt, 2013, Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy, Ann Oncol, 24, 1466, 10.1093/annonc/mdt007 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Powles, 2020, Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma, N Engl J Med, 383, 1218, 10.1056/NEJMoa2002788 Bajorin, 1999, Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J Clin Oncol, 17, 3173, 10.1200/JCO.1999.17.10.3173 Bellmunt, 2010, Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, 28, 1850, 10.1200/JCO.2009.25.4599 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Kang, 2015, Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach, Stat Med, 34, 685, 10.1002/sim.6370 Chen, 1985, The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model, Stat Med, 4, 39, 10.1002/sim.4780040107 Sauerbrei, 1992, A bootstrap resampling procedure for model building: application to the Cox regression model, Stat Med, 11, 2093, 10.1002/sim.4780111607 Apolo, 2013, Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy, J Natl Cancer Inst, 105, 499, 10.1093/jnci/djt015 Galsky, 2013, Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy, Cancer, 119, 3012, 10.1002/cncr.28146 Sonpavde, 2018, Nomogram to assess the survival benefit of new salvage agents for metastatic urothelial carcinoma in the era of immunotherapy, Clin Genitourin Cancer, 16, e961, 10.1016/j.clgc.2018.03.016 Taguchi, 2015, Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: a multi-institutional study, Int J Urol, 22, 638, 10.1111/iju.12766 Pond, 2014, A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma, BJU Int, 113, E137, 10.1111/bju.12564 Scott, 2020, Performance status in cancer: not broken, but time for an upgrade?, J Clin Oncol, 38, 2824, 10.1200/JCO.20.00721 Bersanelli, 2018, Patient performance status and cancer immunotherapy efficacy: a meta-analysis, Med Oncol, 35, 132, 10.1007/s12032-018-1194-4 Sonpavde, 2020, Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors, J Urol, 204, 1173, 10.1097/JU.0000000000001199 Nassar, 2020, A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma, Br J Cancer, 122, 555, 10.1038/s41416-019-0686-0 Ferrucci, 2016, Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol, 27, 732, 10.1093/annonc/mdw016 Bilen, 2018, Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab, Clin Genitourin Cancer, 16, e563, 10.1016/j.clgc.2017.12.015 Jiang, 2018, Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis, Cancer Immunol Immunother, 67, 713, 10.1007/s00262-018-2126-z Guthrie, 2013, The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer, Crit Rev Oncol Hematol, 88, 218, 10.1016/j.critrevonc.2013.03.010 Valero, 2021, Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors, Nat Commun, 12, 729, 10.1038/s41467-021-20935-9 Gonzalez, 2018, Roles of the immune system in cancer: from tumor initiation to metastatic progression, Genes Dev, 32, 1267, 10.1101/gad.314617.118 Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat Rev Cancer, 19, 133, 10.1038/s41568-019-0116-x Ren, 2019, Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB), Onco Targets Ther, 12, 4235, 10.2147/OTT.S199176 Khaki, 2021, A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors, Eur Urol Oncol, 10.1016/j.euo.2020.12.006